203 related articles for article (PubMed ID: 10344911)
1. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
Lamb HM; Wiseman LR
Pharmacoeconomics; 1998 Oct; 14(4):447-59. PubMed ID: 10344911
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of treatment options in advanced breast cancer in the UK.
Brown RE; Hutton J; Burrell A
Pharmacoeconomics; 2001; 19(11):1091-102. PubMed ID: 11735676
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.
Brown RE; Hutton J
Anticancer Drugs; 1998 Nov; 9(10):899-907. PubMed ID: 9890701
[TBL] [Abstract][Full Text] [Related]
4. An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
Benedict A; Cameron DA; Corson H; Jones SE
Pharmacoeconomics; 2009; 27(10):847-59. PubMed ID: 19803539
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
Young M; Plosker GL
Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
[TBL] [Abstract][Full Text] [Related]
7. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
Lister-Sharp D; McDonagh MS; Khan KS; Kleijnen J
Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
[TBL] [Abstract][Full Text] [Related]
8. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine.
Launois R; Reboul-Marty J; Henry B; Bonneterre J
Pharmacoeconomics; 1996 Nov; 10(5):504-21. PubMed ID: 10169397
[TBL] [Abstract][Full Text] [Related]
9. [A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].
Launois RJ; Reboul-Marty JM; Bonneterre J
Bull Cancer; 1997 Jul; 84(7):709-21. PubMed ID: 9339197
[TBL] [Abstract][Full Text] [Related]
10. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of taxane therapy.
Yee GC
Am J Health Syst Pharm; 1997 Dec; 54(24 Suppl 2):S11-5. PubMed ID: 9435927
[TBL] [Abstract][Full Text] [Related]
12. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Verma S; Ilersich AL
Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
Plosker GL; Hurst M
Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel: an update of its use in advanced breast cancer.
Figgitt DP; Wiseman LR
Drugs; 2000 Mar; 59(3):621-51. PubMed ID: 10776837
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain.
Frías C; Cortés J; Seguí MÁ; Oyagüez I; Casado MÁ
Clin Transl Oncol; 2010 Oct; 12(10):692-700. PubMed ID: 20947484
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel and docetaxel. Innovation, but at what cost?
Lønning PE
Pharmacoeconomics; 1995 Jul; 8(1):1-4. PubMed ID: 10155597
[No Abstract] [Full Text] [Related]
17. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
Ravdin PM
Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
[TBL] [Abstract][Full Text] [Related]
18. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer.
Hutton J; Brown R; Borowitz M; Abrams K; Rothman M; Shakespeare A
Pharmacoeconomics; 1996; 9 Suppl 2():8-22. PubMed ID: 10163967
[TBL] [Abstract][Full Text] [Related]
19. Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer.
Dranitsaris G; Elia-Pacitti J; Cottrell W
Pharmacoeconomics; 2004; 22(6):375-87. PubMed ID: 15099123
[TBL] [Abstract][Full Text] [Related]
20. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
Dranitsaris G; Cottrell W; Spirovski B; Hopkins S
J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]